


PHARMACEUTICAL 2019

## ABBOTT LABORATORIES Rank 22 of 371









RealRate

PHARMACEUTICAL 2019



ABBOTT LABORATORIES Rank 22 of 371

The relative strengths and weaknesses of ABBOTT LABORATORIES are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ABBOTT LABORATORIES compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 366% points. The greatest weakness of ABBOTT LABORATORIES is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 112% points.

The company's Economic Capital Ratio, given in the ranking table, is 187%, being 518% points above the market average of -331%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 14,632,000        |
| Cost of Goods Sold                          | 12,706,000        |
| Intangible Assets                           | 42,196,000        |
| Liabilities, Current                        | 9,012,000         |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 2,782,000         |
| Other Compr. Net Income                     | -1,192,000        |
| Other Expenses                              | 3,543,000         |
| Other Liabilities                           | 0                 |
| Other Net Income                            | 83,000            |
| Property and Equipment                      | 7,563,000         |
| Research and Development                    | 2,300,000         |
| Revenues                                    | 30,578,000        |
| Selling, General and Administrative Expense | 9,744,000         |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 67,173,000        |
| Liabilities              | 9,012,000         |
| Expenses                 | 28,293,000        |
| Stockholders Equity      | 58,161,000        |
| Net Income               | 2,368,000         |
| Comprehensive Net Income | 1,772,000         |
| Economic Capital Ratio   | 187%              |

